An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 131, Issue 5, 2005, Pages 418-429

  Yoo, George H ^a   Subramanian, Geetha ^a   Boinpally, Ramesh R ^a   Iskander, Andrew ^a   Shehadeh, Nasfat ^a   Oliver, Jeffrey ^a   Ezzat, Waleed ^a   Piechocki, Marie P ^a   Ensley, John F ^a   Lin, Ho Sheng ^a   Shibuya, Terry Y ^b   Polin, Lisa ^a   Parchment, Ralph E ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; CYCLIN A; CYCLIN B; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; PROTEIN P21; PROTEIN P27;

ALOPECIA; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, SCID; TAXOIDS;

EID: 21044441004     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.131.5.418     Document Type: Article

References (43)

1. al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317.
2. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
3. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92-98.
4. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081-2086.
5. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685-1690.
6. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst. 1996;88:890-899.
7. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
8. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys. 1992;23:705-713.
9. Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol. 1998;21:482-486.
10. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol. 1998;16:1331-1339.
11. Schoffski P, Catimel G, Planting AS, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 1999;10:119-122.
12. Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999;17:3503-3511.
13. Couteau C, Chouaki N, Leyvraz S, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 1999;81:457-462.
14. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19:1096-1104.
15. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995;22(2 suppl 4):3-16.
16. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1:32-40.
17. Belani CP. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002;29:4-9.
18. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002;29:22-27.
19. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003;97:412-418.
20. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. 2001;12(suppl 1):S21-S24.
21. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist. 2000;5:199-208.
22. Colevas AD, Adak S, Amrein PC, Barton JJ, Costello R, Posner MR. A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann Oncol. 2000;11:535-539.
23. Murphy B, Li Y, Cella D, Karnad A, Hussain M, Forastiere A. Phase III study comparing cisplatin (C) & 5-flurouracil (F) versus cisplatin & paclitaxel (T) in metastatic/ recurrent head & neck cancer (MHNC). In: Proceedings, Annual Meeting American Society of Clinical Oncology. Alexandria, Va: American Society of Clinical Oncology Publications; 2001:894.
24. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8:878-884.
25. Burris HA III, Vogel CL, Castro D, et al. Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg. 1998;118:496-503.
26. Clayman GL, Dreiling LK. Injectable modalities as local and regional strategies for head and neck cancer. Hematol Oncol Clin North Am. 1999;13:787-810.
27. Wenig BL, Werner JA, Castro DJ, et al. The role of intratumoral therapy with cisplatin/ epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2002;128:880-885.
28. Yeudall WA, Jakus J, Ensley JF, Robbins KC. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog. 1997;18:89-96.
29. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience, I: preclinical experience. Anticancer Drugs. 1995;6:339-368.
30. Lee SH, Yoo SD, Lee KH. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;724:357-363.
31. Piechocki MP, Lonardo F, Ensley JF, Nguyen T, Kim H, Yoo GH. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res. 2002;8:870-877.
32. Yoo GH, Piechocki MP, Ensley JF, et al. Docetaxel-induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res. 2002;8:3910-3921.
33. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16:187-196.
34. Mok TS, Kanekal S, Lin XR, et al. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. Cancer. 2001;91:2369-2377.
35. Krag DN, Theon AP, Schneider PD, Goodnight JE. Intralesional cis-diamminedichloroplatinum and purified collagen treatment of human metastatic malignancies: a feasibility study. J Surg Oncol. 1990;43:83-87.
36. Monga SP, Wadleigh R, Sharma A, et al. Intratumoral therapy of cisplatin/ epinephrine injectable gel for palliation in patients with obstructive esophageal cancer. Am J Clin Oncol. 2000;23:386-392.
37. Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer. 1999;85:980-987.
38. Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: a study on 207 patients. Cancer. 1992;69:925-929.
39. Livraghi T, Lazzaroni S, Pellicano S, Ravasi S, Torzilli G, Vettori C. Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia. AJR Am J Roentgenol. 1993;161:1065-1069.
40. Livraghi T, Lazzaroni S, Meloni F, Torzilli G, Vettori C. Intralesional ethanol in the treatment of unresectable liver cancer. World J Surg. 1995;19:801-806.
41. Orlando A, D'Antoni A, Camma C, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol. 2000;95:2921-2927.
42. Kanduc D, Mittelman A, Serpico R, et al. Cell death: apoptosis versus necrosis (review). Int J Oncol. 2002;21:165-170.
43. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res. 2003;283:1-16.